How Good Were Celldex Therapeutics' Latest Clinical Results?
Celldex Therapeutics (NASDAQ: CLDX) recently announced results from a phase 1b clinical study evaluating CDX-0159 in treating two of the most common forms of chronic inducible hives. In this Motley Fool Live video recorded on July 14, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss just how good the biotech's latest clinical results were.
Source Fool.com
